ProQR Therapeutics N.V

NASDAQ:PRQR   3:54:22 PM EDT
0.68
+0.01 (+1.53%)
Earnings Announcements

Proqr Announces First Quarter 2022 Operating And Financial Results

Published: 05/05/2022 20:39 GMT
(PRQR) - Proqr Announces First Quarter 2022 Operating and Financial Results.
Q1 Loss per Share EUR 0.20.
Cash Runway Into 2025.
Proqr Therapeutics - Enrollment Ongoing in Sirius, a Phase 2/3 Trial of Ultevursen , for Ush2a-mediated Usher Syndrome and Retinitis Pigmentosa.
Q1 Earnings per Share View EUR -0.24 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0.95 Million
Adjusted EPS is expected to be -$0.23

Next Quarter Revenue Guidance is expected to be $0.91 Million
Next Quarter EPS Guidance is expected to be -$0.22

More details on our Analysts Page.